Compugen's Q4, FY 2010 Revenues Rise | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Compugen today reported increased revenues for its fourth quarter and fiscal-year 2010 on higher fees and milestones.

The Tel Aviv, Israel-based firm, which has developed in silico drug discovery platforms, reported total revenues of $190,000 for the three-month period ended Dec. 31, 2010, compared to $25,000 for the fourth quarter of 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.